Showing Articles
Medicare Patient Demographics at 340B Covered Entities
ADVI SAVEs (Strategic Analytics and Value Economics) analyzed Medicare fee-for-service (FFS) claims data from 2018 through 2020 to determine the demographic characteristics of patients served at 340B covered entities. Specifically, we analyzed and compared inpatient claims at 340B Disproportionate Share Hospitals (“DSH”) hospitals to outpatient claims at 340B DSH hospitals and child sites to determine […]
Read moreANALYSIS OF 2021 PART B DRUG DISCARDED UNITS IN LIGHT OF NEWLY RELEASED GUIDANCE IN CY 2023 MEDICARE PHYSICIAN FEE SCHEDULE PROPOSED RULE
Part B Discarded Drug Units for 2021 The Centers for Medicare and Medicaid Services (CMS) requires all providers and suppliers to report the “JW” HCPCS modifier on Part B drug claims for discarded drugs and biologicals beginning January 1, 2017. CMS reports aggregate discarded units, also referred to as “wastage,” through the Medicare Part B […]
Read more
Excitement, Anticipation, Questions Await as ASCO 2022 Begins
Will a new targeting therapy for HER2 breast cancer show promise for more patients? By Dr. Michael Kolodziej There is an old adage that “absence makes the heart grow fonder.” This holds particularly true for this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, which gets underway today in Chicago. As I mentioned in […]
Read more
ASCO 2022 is Back the Way it Should Be, in Person
By Dr. Michael Kolodziej On June 3, thousands of oncologists, oncology researchers and biopharmaceutical companies will convene at the McCormick Place Convention Center in Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting. After COVID-19 forced this industry premier event to be conducted virtually the past few years, there will be much shared […]
Read more